Your browser doesn't support javascript.
loading
Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapy.
Kowalchuk, Roman O; Mullikin, Trey C; Florez, Marcus; De, Brian S; Spears, Grant M; Rose, Peter S; Siontis, Brittany L; Kim, Dong Kun; Costello, Brian A; Morris, Jonathan M; Marion, Joseph T; Johnson-Tesch, Benjamin A; Gao, Robert W; Shiraishi, Satomi; Lucido, John J; Trifiletti, Daniel M; Olivier, Kenneth R; Owen, Dawn; Stish, Bradley J; Waddle, Mark R; Laack, Nadia N; Park, Sean S; Brown, Paul D; Ghia, Amol J; Merrell, Kenneth W.
Afiliación
  • Kowalchuk RO; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Mullikin TC; Department of Radiation Oncology, Duke University, Durham, North Carolina, USA.
  • Florez M; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • De BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Spears GM; Department of Statistics, Mayo Clinic, Rochester, Minnesota, USA.
  • Rose PS; Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Siontis BL; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kim DK; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Costello BA; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Morris JM; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Marion JT; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Johnson-Tesch BA; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Gao RW; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Shiraishi S; Department of Medical Physics, Mayo Clinic, Rochester, Minnesota, USA.
  • Lucido JJ; Department of Medical Physics, Mayo Clinic, Rochester, Minnesota, USA.
  • Trifiletti DM; Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Olivier KR; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Owen D; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Stish BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Waddle MR; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Laack NN; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Park SS; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Brown PD; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Ghia AJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Merrell KW; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Cancer ; 129(6): 956-965, 2023 03 15.
Article en En | MEDLINE | ID: mdl-36571507
ABSTRACT

BACKGROUND:

This study was aimed at developing and validating a decision-making tool predictive of overall survival (OS) for patients receiving stereotactic body radiation therapy (SBRT) for spinal metastases.

METHODS:

Three hundred sixty-one patients at one institution were used for the training set, and 182 at a second institution were used for external validation. Treatments most commonly involved one or three fractions of spine SBRT. Exclusion criteria included proton therapy and benign histologies.

RESULTS:

The final model consisted of the following variables and scores Spinal Instability Neoplastic Score (SINS) ≥ 6 (1), time from primary diagnosis < 21 months (1), Eastern Cooperative Oncology Group (ECOG) performance status = 1 (1) or ECOG performance status > 1 (2), and >1 organ system involved (1). Each variable was an independent predictor of OS (p < .001), and each 1-point increase in the score was associated with a hazard ratio of 2.01 (95% confidence interval [CI], 1.79-2.25; p < .0001). The concordance value was 0.75 (95% CI, 0.71-0.78). The scores were discretized into three groups-favorable (score = 0-1), intermediate (score = 2), and poor survival (score = 3-5)-with 2-year OS rates of 84% (95% CI, 79%-90%), 46% (95% CI, 36%-59%), and 21% (95% CI, 14%-32%), respectively (p < .0001 for each). In the external validation set (182 patients), the score was also predictive of OS (p < .0001). Increasing SINS was predictive of decreased OS as a continuous variable (p < .0001).

CONCLUSIONS:

This novel score is proposed as a decision-making tool to help to optimize patient selection for spine SBRT. SINS may be an independent predictor of OS.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Columna Vertebral / Radiocirugia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Columna Vertebral / Radiocirugia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article